NEW HAVEN, Conn., May 16, 2007 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overview and update on the Company’s clinical programs in HIV, HCV and serious bacterial infections at the Sixth Annual JMP Securities Research Conference. The Company presentation will take place on Wednesday, May 23, 2007 at 10:30 a.m. PST (1:30 p.m. EST) at the Ritz-Carlton, San Francisco.
